Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Klaria Pharma Holding Q1 2023 - No headache just yet

Klaria Pharma Holding

Redeye comments on Klaria Pharma’s Q1 2023 report. The company reports continued validation of its epinephrine alginate film. We regard The Swedish Financial Supervisory Authority´s decision to investigate Klaria Pharma as a non-case-altering event. We believe Klaria potentially finding and signing a licensing agreement with a commercialisation partner for its sumatriptan alginate film in 2023 is essential for a positive share development. We make adjustments to our estimates and valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Klaria Pharma Holding Q1 2023 - No headache just yet

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.